‹ ›
MYP_153729
← PREVIOUS NEXT → BACK
Basic Information
SARSWW-Vb(1169-1194)
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
28 amino acids
C147H230N36O46S
Standard
Sequence
AACEVAKNLNESLIDLQELGKYEQYIKW
Physicochemical Analysis
3269.68 Da
4.59
-2.21
-2.42
-0.0788
-0.41
0.53
0.01
46.16
104.64
0.1071
8480.00
8480.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1362.42
-9.74
46.0
45.0
112.0
230.0
4.0
31.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0231241 VERIFIED: YES
Provenance & Taxonomy
Severe acute respiratory syndrome-related coronavirus [Virus]
S2-derived peptide
694009
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
Severe acute respiratory syndrome coronavirus
2 μM
IC50
PaperInhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein PMID16616792 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/16616792/
RECORD: Rec_0235640 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
synthetic linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-SARS-COV Entry inhibition
SARS-CoV | E6 cells
Mammalian: 4.4 h; Yeast: >20 h; E. coli: >10 h
PaperInhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 Sep;120(1-2):146-55. | DOI:10.1016/j.virusres.2006.03.001 | PMID:16616792 PMID16616792 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/16616792/
RECORD: Rec_0247059 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
SARS-CoV:inhibition of plaque information on Vero E6 cells
42 %
Inhibition
PaperPubMed PMID: 16616792 PMID16616792 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/16616792/
RECORD: Rec_0260121 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
toxicity against Vero E6 cells up to 30 μM
30 μM
Cytotoxicity
PaperPubMed PMID: 16616792 PMID16616792 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/16616792/
RECORD: Rec_0398818 VERIFIED: YES
Provenance & Taxonomy
Severe acute respiratory syndrome-related coronavirus [Virus]
Virus-derived peptide
694009;0
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
SARS coronavirus (Fusion); Vero E6
42 %
Plaque assay
PaperInhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | PMID:16616792 PMID16616792 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/16616792/
FIRST PREV 1 2 3 NEXT LAST
Showing 5 records on this page · Page 2 of 3